antibodies
The Dutch company is developing a pipeline of vectorized antibodies to clear pathological protein aggregates from affected cells in neurodegenerative disorders.
Angle, Eisai Agree to Study HER2 Assay
Angle will study the use of its Portrait HER2 assay to identify breast cancer patients who would benefit from anti-HER2 antibody-drug conjugate therapy.
Junshi Biosciences Eyeing Toripalimab Regulatory Submission in Triple-Negative Breast Cancer
The Shanghai-based firm plans to hold regulatory discussions following a positive data readout from its Phase III TORCHLIGHT study.
Abpro Licenses HER2-Targeteing Bispecific Antibody to Celltrion
Celltrion will pay Abpro up to $1.75 billion to obtain the worldwide commercialization rights for the investigational cancer therapy ABP 102.
Biocytogen Pharmaceuticals, Guangzhou FineImmune Biotechnology Ink Cell Therapy Partnership
The Chinese firms will use Biocytogen's platform to identify antibody targets and FineImmune's platform to develop these targets into cell therapies for solid tumors.